Colgate-Palmolive Likely to See Organic Sales Growth Improvement, Morgan Stanley Says

MT Newswires Live
2025/11/04

Colgate-Palmolive's (CL) Q3 results indicated a soft quarter but the company will likely start seeing an improvement from here in organic sales growth as "comparisons ease and temporary pressure points from Q3 dissipate," Morgan Stanley said in a note emailed Monday.

The investment firm said that Colgate's Q3 results showed it missed Street estimates for organic sales growth by 90 basis points, which was more or less in line with expectations, and gross margins by 100 basis points, which was "more unexpected."

Morgan Stanley highlighted the fact that Colgate has kept its 2025 EPS guidance with "SG&A/tax favorability driving Q3 EPS upside" but the investment firm believes Colgate has "moved slightly lower within its FY EPS range."

Morgan Stanley kept its overweight rating on the company, but cut Colgate's price target to $87 from $96, citing a "lower multiple reflecting structurally lower [home and personal care] sector topline growth."

Price: 75.61, Change: -1.44, Percent Change: -1.88

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10